The Protective Potential Role of ACE2 against COVID-19

Due to the coronavirus disease 2019 (COVID-19), researchers all over the world have tried to find an appropriate therapeutic approach for the disease. The angiotensin-converting enzyme 2 (ACE2) has been shown as a necessary receptor to cell fusion, which is involved in infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is commonly crucial for all organs and systems. When ACE2 is downregulated via the SARS-CoV-2 spike protein, it results in the angiotensin II (Ang II)/angiotensin type 1 receptor axis overactivation. Ang II has harmful effects, which can be evidenced by dysfunctions in many organs experienced by COVID-19 patients. ACE2 is the SARS-CoV-2 receptor and has an extensive distribution; thus, some COVID-19 cases experience several symptoms and complications. We suggest strategy for the potential protective effect of ACE2 to the viral infection. The current review will provide data to develop new approaches for preventing and controlling the COVID-19 outbreak.

[1]  Nahid Abbasi Khoshsirat,et al.  Cerebral venous sinus thrombosis following intracerebral hemorrhage after COVID‐19 AstraZeneca vaccination: A case report , 2022, Clinical case reports.

[2]  M. Boulton,et al.  SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes , 2020, Diabetes.

[3]  Quanlong Jiang,et al.  Individual variation of the SARS‐CoV‐2 receptor ACE2 gene expression and regulation , 2020, Aging cell.

[4]  Nehla Banu,et al.  Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications , 2020, Life Sciences.

[5]  T. Hussain.  Faculty Opinions recommendation of Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. , 2020 .

[6]  Martin Stahl,et al.  Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 , 2020, Cell.

[7]  T. Drueke,et al.  Blockade of SARS-CoV-2 infection by recombinant soluble ACE2 , 2020, Kidney International.

[8]  Quynh Nguyen,et al.  Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System , 2020, Circulation research.

[9]  D. Diz,et al.  COVID-19, ACE2, and the cardiovascular consequences , 2020, American journal of physiology. Heart and circulatory physiology.

[10]  Yan Wang,et al.  Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19 , 2020, Journal of medical virology.

[11]  D. Batlle,et al.  Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? , 2020, Clinical science.

[12]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[13]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[14]  Haibo Zhang,et al.  Recombinant human ACE2: acing out angiotensin II in ARDS therapy , 2017, Critical Care.

[15]  Akram Khan,et al.  A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome , 2017, Critical Care.

[16]  Suhn Hee Kim,et al.  Angiotensin-(1-5), an active mediator of renin-angiotensin system, stimulates ANP secretion via Mas receptor , 2016, Peptides.

[17]  H. Jia.  Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease , 2016, Shock.

[18]  H. Yoon,et al.  Age-Associated Changes in the Vascular Renin-Angiotensin System in Mice , 2016, Oxidative medicine and cellular longevity.

[19]  P. Zhu,et al.  Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus , 2016, Scientific Reports.

[20]  Arthur S Slutsky,et al.  Mechanical Stress and the Induction of Lung Fibrosis via the Midkine Signaling Pathway. , 2015, American journal of respiratory and critical care medicine.

[21]  J. Penninger,et al.  ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity , 2015, Diabetes.

[22]  S. Krähenbühl,et al.  Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects , 2013, Clinical Pharmacokinetics.

[23]  J. Penninger,et al.  Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[24]  R. Lutter,et al.  Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin‐(1–7) or an angiotensin II receptor antagonist , 2011, The Journal of pathology.

[25]  J. Penninger,et al.  Prevention of Angiotensin II–Mediated Renal Oxidative Stress, Inflammation, and Fibrosis by Angiotensin-Converting Enzyme 2 , 2011, Hypertension.

[26]  J. Penninger,et al.  Angiotensin Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis and Diastolic Dysfunction , 2010 .

[27]  J. Penninger,et al.  Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters , 2010, Pharmacology & Therapeutics.

[28]  A. Loeckinger,et al.  Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets , 2010, Critical care medicine.

[29]  J. Penninger,et al.  Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy , 2009, Diabetes.

[30]  Bibekanand Mallick,et al.  MicroRNome Analysis Unravels the Molecular Basis of SARS Infection in Bronchoalveolar Stem Cells , 2009, PloS one.

[31]  Christian Drosten,et al.  Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 , 2009, Journal of Virology.

[32]  D. Brenner,et al.  Angiotensin‐converting‐enzyme 2 inhibits liver fibrosis in mice , 2009, Hepatology.

[33]  Arthur S Slutsky,et al.  Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. , 2008, American journal of physiology. Heart and circulatory physiology.

[34]  R. Kreienberg,et al.  Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. , 2008, Gynecologic oncology.

[35]  M. Chappell.  Emerging Evidence for a Functional Angiotensin-Converting Enzyme 2-Angiotensin-(1-7)-Mas Receptor Axis: More Than Regulation of Blood Pressure? , 2007, Hypertension.

[36]  D. Ganten,et al.  Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. , 2007, American journal of physiology. Heart and circulatory physiology.

[37]  Z. Li,et al.  Expression of elevated levels of pro‐inflammatory cytokines in SARS‐CoV‐infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS† , 2006, The Journal of pathology.

[38]  J. Penninger,et al.  Angiotensin-converting enzyme II in the heart and the kidney. , 2006, Circulation research.

[39]  Xudong Xie,et al.  Age- and gender-related difference of ACE2 expression in rat lung , 2005, Life Sciences.

[40]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[41]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[42]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[43]  T. Greenough,et al.  What’s new in the renin-angiotensin system? , 2004, Cellular and Molecular Life Sciences CMLS.

[44]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[45]  M. Crackower,et al.  Angiotensin-converting enzyme 2 is an essential regulator of heart function , 2002, Nature.

[46]  T. Parsons,et al.  Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase* , 2002, The Journal of Biological Chemistry.

[47]  N. Hooper,et al.  The angiotensin-converting enzyme gene family: genomics and pharmacology. , 2002, Trends in pharmacological sciences.

[48]  A. Allred,et al.  Pathways of angiotensin-(1-7) metabolism in the kidney. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  Nigel M. Hooper,et al.  A Human Homolog of Angiotensin-converting Enzyme , 2000, The Journal of Biological Chemistry.

[50]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[51]  K. Baker,et al.  The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? , 1999, Circulation research.

[52]  P. Mannon,et al.  Regulation of blood pressure by the type 1A angiotensin II receptor gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[53]  B. Berk,et al.  The biology of angiotensin II receptors. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[54]  D. Ganten,et al.  Morphology, physiology, and molecular biology of renin secretion. , 1990, Physiological reviews.

[55]  J. Egido,et al.  Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. , 2001, Contributions to nephrology.